Pharmaceutical Companies Performance Tables 2010
- 1,890 views
Pharmaceutical Company Performance TablesThe answers to thousands of key questions are in the new 2010 editionIn today's challenging market, business planners and commercial management must ask ...
Pharmaceutical Company Performance TablesThe answers to thousands of key questions are in the new 2010 editionIn today's challenging market, business planners and commercial management must ask themselves some key questions, such as...Who are the winners and losers in terms of revenue growth' Which companies have succeeded in maintaining or growing profits' Overall R&D investment from the top 10 companies fell between 2008 and 2009 by US$421 million from US$57.54 billion to US$57.12 billion ' yet some companies maintained or expanded R&D spend. Who were they' Who are the fastest growers' 10 companies with joint 2005 sales of US$2.55 billion posted sales of $US13.06 billion in 2009. Who were they' Which companies are cash rich or cash poor' Pharmaceutical Company Performance TablesThe answers to thousands of key questions are in the new 2010 editionThis essential fully-updated business reference report compares and contrasts the performance and fortunes of leading pharmaceutical companies and places them in easy-to-read tables. Importantly, in addition to rankings, the new edition of the report includes the individual results for 162 companies and up to five years of key data from the balance sheet, income statement and cash flow. Key Facts & Benefits of this report:Full 2009 year-end figures Contains a wide range of detailed performance rankings for more than 160 leading pharmaceutical companies Includes individual company results Provides up to five years of trend data Available in print or pdf with web access included free of charge!Trends affecting the global industry The challenging economic environment continues to affect health spending in many countries which has impacted the pharmaceutical industry's commercial performance. Issues which are affecting companies' performance, include...The number of blockbuster drugs which have lost patent protection, and the number is set to rise over the coming years, have not been replaced by new products offering significant therapeutic advances Those products which have been launched ' increasingly in the biological area ' have attracted criticism and objection from health payers due to their high costMany companies continue to post rising revenues and increasing profits, although for many it is against a background of cost cutting Mergers and acquisitions, and especially technology/product acquisition, have taken an increasing role in market entry/expansion plansGeneric competition continues to erode the profits of off-patent products, although spending constraints and rising competition are creating pressure in the generic sector.Pharmaceutical Companies Performance TablesA unique opportunity to assess companies' financial and operating performances. Use it for... Competitor analysis Acquisition targeting Partnering and licensing background PR and Marketing Performance benchmarking Just some of the 162 companies in the 2010 edition... Abbott Laboratories Abraxis BioScience Ajinomoto Alcon Laboratories Allergan Amgen Amylin Pharmaceuticals Astellas AstraZeneca Baxter International Bayer Biogen Idec Boehringer Ingelheim Bristol-Myers Squibb BTG International Celgene Chugai CSL Limited Cubist Pharmaceuticals Cytokinetics Daiichi Sankyo Dainippon Sumitomo Pharma Dendreon Dr Reddy's Labs Egis Eisai Elan Eli Lilly Endo Pharmaceuticals Enzon Pharmaceuticals Eurand Forest Laboratories Gedeon Richter Genzyme Gilead Sciences GlaxoSmithKline Hospira Human Genome Sciences ImmunoGen Incyte Inspire Pharmaceuticals Ipsen Isis Pharmaceuticals Johnson & Johnson KRKA Kyowa Kirin Lundbeck Mannkind Merck & Co Merck KGaA Mitsubishi Tanabe Pharma Mylan Laboratories Nipro Novartis Novo Nordisk NPS Pharmaceuticals Nycomed Ono Pharmaceuticals Orion OSI Pharmaceuticals Otsuka Pfizer Procter & Gamble Ranbaxy Recordati Regeneron Pharmaceuticals Roche sanofi-aventis Sawai Shionogi Shire Pharmaceuticals Stada Arzneimittel Takeda Teva Pharmaceutical Industries Theravance UCB Vertex Pharmaceuticals XOMA ZymoGene
- Total Views
- Views on SlideShare
- Embed Views